Advertisement
Canada markets open in 2 hours 46 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7322
    -0.0001 (-0.01%)
     

  • CRUDE OIL

    83.87
    +0.30 (+0.36%)
     

  • Bitcoin CAD

    87,770.10
    +1,054.56 (+1.22%)
     

  • CMC Crypto 200

    1,388.91
    -7.62 (-0.55%)
     

  • GOLD FUTURES

    2,358.20
    +15.70 (+0.67%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,741.25
    +173.75 (+0.99%)
     

  • VOLATILITY

    15.63
    +0.26 (+1.69%)
     

  • FTSE

    8,111.35
    +32.49 (+0.40%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6823
    +0.0002 (+0.03%)
     

Biofrontera Initiated with a Buy at Roth Capital, Stock Surges

Investing.com
·1 min read

By Sam Boughedda

Investing.com — Biopharmaceutical firm Biofrontera Inc (NASDAQ:BFRI) has seen its share price jump 135% to $6.19 in Wednesday trading after analysts at Roth Capital initiated the stock with a buy rating.

The stock, which made its public debut on October 28, had been steadily declining since touching an intraday high of $4.99 at the start of November.

Roth analyst Jonathan Aschoff set a 12-month price target of $20 for the shares, saying they project future U.S. revenue from the Ameluz and Xepi treatments in actinic keratosis and impetigo, respectively.

"Our initial valuation excludes potential commercial upside from any potential future programs, given BFRI’s clear focus on its two currently approved drugs," Aschoff said.

ADVERTISEMENT

On Tuesday, Biofrontera announced that it will release its third-quarter results on November 30.

Related Articles

Biofrontera Initiated with a Buy at Roth Capital, Stock Surges

S&P 500 Cuts Losses as Tech Selloff Eases, Cyclicals Shine

U.S. puts Chinese firms helping military on trade blacklist